Biological Drugs Market

List of Figures 

FIG. 1 Biological Drugs Market, by therapeutic proteins, mAbs and vaccine

FIG. 2 Geriatric population in major countries, % in older ages (2000-2050) 

FIG. 3 Biological Drugs Market: Porter’s five force analysis

FIG. 4 Global market for biological drugs, by geography 2013 (% share) 

FIG. 5 Global market for biological drugs, by segment 2013 (% share) 

FIG. 6 Global market for Enbrel, by geography 2013 (% share) 

FIG. 7 Global market for Lantus, by geography 2013 (% share) 

FIG. 8 Global market for Neulasta, by geography 2013 (% share) 

FIG. 9 Global market for Avonex, by geography 2013 (% share) 

FIG. 10 Global market for NovoLog, by geography 2013 (% share) 

FIG. 11 Global market for Rebif, by geography 2013 (% share) 

FIG. 12 Global market for Humalog, by geography 2013 (% share) 

FIG. 13 Global market for Aranesp, by geography 2013 (% share) 

FIG. 14 Global market for Epogen, by geography 2013 (% share) 

FIG. 15 Global market for Levemir, by geography 2013 (% share) 

FIG. 16 Global market for Victoza, by geography 2013 (% share) 

FIG. 17 Global market for Betaseron, by geography 2013 (% share)

FIG. 18 Global market for Neupogen, by geography 2013 (% share) 

FIG. 19 Global market for Eylea, by geography 2013 (% share) 

FIG. 20 Global market for Humira by geography 2013 (% share) 

FIG. 21 Global market for Remicade, by geography 2013 (% share) 

FIG. 22 Global market for Rituxan, by geography 2013 (% share) 

FIG. 23 Global market for Avastin, by geography 2013 (% share)

FIG. 24 Global market for Herceptin, by geography 2013 (% share)

FIG. 25 Global market for Lucentis, by geography 2013 (% share) 

FIG. 26 Global market for Prevnar 13, by geography 2013 (% share) 

FIG. 27 Global market for Gardasil, by geography 2013 (% share) 

FIG. 28 Global market for Fluzone, by geography 2013 (% share) 

FIG. 29 Global market for Varivax, by geography 2013 (% share) 

FIG. 30 Global market for Cervarix, by geography 2013 (% share)

FIG. 31 The North American market for biological drugs, by country 2013 (% share) 

FIG. 32 The North American market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 33 The North American market for biological drugs, by mAb 2013 (% share) 

FIG. 34 The North American market for biological drugs, by vaccine 2013 (% share)

FIG. 35 The European market for biological drugs, by country 2013 (% share)

FIG. 36 The European market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 37 The European market for biological drugs, by mAb 2013 (% share) 

FIG. 38 The European market for biological drugs, by vaccine 2013 (% share)

FIG. 39 The Asian market for biological drugs, by country 2013 (% share) 

FIG. 40 The Asian market for biological drugs, by therapeutic protein 2013 (% share) 

FIG. 41 The Asian market for biological drugs, by mAb 2013 (% share) 

FIG. 42 The Asian market for biological drugs, by vaccine 2013 (% share) 

FIG. 43 Competitive landscape of biological drugs market 

FIG. 44 Pfizer revenue and net income 2011-2013 (USD million) 

FIG. 45 Abbott net sales and net earnings 2011-2013 (USD million) 

FIG. 46 Novartis net sales and net income 2011-2013 (USD million) 

FIG. 47 Lilly revenue and net income 2011-2013 (USD million)

FIG. 48 GlaxoSmithKline turnover and profit 2011-2013 (USD million) 

FIG. 49 Bristol-Myers Squibb revenue and net earnings 2011-2013 (USD million) 

FIG. 50 Merck sales and net income 2011-2013 (USD million) 

FIG. 51 Amgen revenue and net income 2011-2013 (USD million) 

FIG. 52 Baxter net sales and net income 2011-2013 (USD million) 

FIG. 53 Biogen Idec revenue and net income 2011-2013 (USD million)